A team of researchers led by biomedical scientist Declan F. McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair…
Read More
Potential drug target revealed to help more children survive a lethal heart defect
When children are born with hypoplastic left heart syndrome (HLHS), they require a series of major surgical procedures to survive. But even with a repaired heart, as many as one in four children die from complications before age 25. Now,…
Read More